Dermatopathology IHC panel

Dermatopathology IHC assay panel icon
Deliver diagnostic confidence with the dermatopathology IHC panel

Melanoma is a malignancy of the melanocytes, and histology is the gold standard for distinguishing malignant cells from benign cells1. We offer over 50 cornerstone and novel dermatopathology ready-to-use reagents, including key IHC and FITC antibodies, which aid in melanoma diagnosis, basal cell carcinoma diagnosis, squamous cell carcinoma diagnosis and diagnosis of other dermatological malignancies.

Our robust menu of tools aid in dermatopathology diagnostics and treatment. Our portfolio of immunohistochemistry detection products delivers the high sensitivity and specificity you need from your assays. Our antibodies are ready-to-use on the fully-automated VENTANA BenchMark IHC/ISH staining platforms, reducing the time-to-result and resources required with manual or semi-automated solutions.

Featured assays

SOX-10 (SP267)
SOX-10 (SP267) Rabbit Monoclonal Primary Antibody

SOX-10 (SP267) Rabbit Monoclonal Primary Antibody is intended for laboratory use in the detection of the SOX-10 protein in formalin-fixed, paraffin-embedded tissue stained on BenchMark immunohistochemical (IHC/ISH) automated slide stainers. SOX-10 is a nuclear transcription factor that participates in neural crest development and in the specification and differentiation of cells of melanocytic lineage.2

CONFIRM anti-MART-1/melan A (A103) Mouse Monoclonal Primary Antibody

CONFIRM anti-MART-1/melan A (A103) Mouse Monoclonal Primary Antibody is a mouse monoclonal antibody (IgG1) directed against melan A. Positive staining may aid in the differentiation of melanoma.3

Stain - Anti-PRAME (EPR20330) Rabbit Monoclonal Primary Antibody
Anti-PRAME (EPR20330) Rabbit Monoclonal Primary Antibody

The anti-PRAME (EPR20330) Rabbit Monoclonal Primary Antibody detects the overexpression of the tumor-associated antigen, PReferentially expressed Antigen in MElanoma (PRAME), in formalin-fixed paraffin embedded tissue. Positive staining may aid in the differentiation of benign versus malignant melanocytic lesions.4,5

Screenshot of doc library

Take an in-depth look at our full dermatopathology cancer IHC assay panel.

Search our product catalogs and documentation library in eLabDoc.


  1. Damanpour, S. Grichnik, J. Conceptual approach to early melanoma detection: models, issues and challenges. Melanoma Manag. 2015 2 (4): 327-337.
  2. Aphivatanasiri C, Li J, Chan R, Jamidi SK, Tsang JY, Poon, IK, Shao Y, Tong J, To KF, Chan SK, Tam F, Cheung SY, Sheas KH, Tse GM. Combined SOX10 GATA3 is most sensitive in detecting primary and metastatic breast cancers: a comparative study of breast markers in multiple tumors. Breast Cancer Research and Treatment. 2020; 184: 11-21.
  3. Patrascu OM, Costache M, Dumitru AV, Mehotin CN, Sajin M, Lazaroiu AM. Expression of Bcl-2, Melan A and HMB-45 in Dysplastic Nevi. MAEDICA. 2016;11(5):38-43.
  4. Lezcano, C. et al. PRAME expression in melanocytic tumors.  Am J Surg Pathol 2018;42(11):1456-1465.
  5. Lezcano, C. et al. PRAME immunohistochemistry as an ancillary test for the assessment of melanocytic lesions. Surg Pathol Clin 2021 Jun;14(2):165-175